Boule Diagnostics appoints new SVP Commercial Operations

Kiarash Farr has been appointed Senior Vice President Commercial Operations of Boule Diagnostics and member of the Group Management Team. He succeeds Claes Blanche who has communicated that he wants to phase out of his current role and take a part time consultant role for Boule. Kiarash Farr will assume the position as of March 1, 2018.

Kiarash most recently served as Director Commercial Operations EMEA of Hycor Biomedical LLC, an American corporation specializing in the manufacture and supply of high-quality in vitro diagnostic products. His previous roles have included Sales Director Key Account at Thermo Fisher Scientific, Global Sales Director, Director of Global Business Development and Sales Director Asia Pacific at IBA, Sales Manager at Scanditronix Wellhöfer and Product Development Manager at Scanditronix Medical. During his career Kiarash has been based in Sweden, India and China. Kiarash holds a Master of Science in Engineering Physics from Stockholm Royal Institute of Technology (KTH), and has also studied Medical Engineering at Karolinska University Hospital as well as Management at INSEAD, France.

”We are very pleased that Kiarash is joining Boule, he brings solid experience from international sales and marketing, distributor management and strategic business development. With his strong drive and experience from the In Vitro Diagnostics market and international business leadership, he will contribute to developing Boule to the next level. We also thank Claes Blanche for his years of successful commercial leadership at Boule, and we are pleased that he will continue to support the future development of Boule in a consultant role” says Fredrik Dalborg, CEO Boule Diagnostics.

For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46 705-58 51 05

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a rapidly growing global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden and the USA. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com 

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET, December 1, 2017.

Release